Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694160 | 0.81 | AR (0.46) | TRPA1ALDH1A1 | |
| SCHEMBL27854069 | 0.79 | CA2 (0.39) | ALDH1A1TSHRTDP1CA2PTPN5 | |
| SCHEMBL2282082 | 0.79 | TRPA1 (0.41) | TRPA1ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL29833702 | 0.78 | ALDH1A1 (0.46) | TRPA1ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL291792 | 0.78 | ALDH1A1 (0.46) | TRPA1ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL28929342 | 0.77 | ALDH1A1 (0.39) | TRPA1ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL1368412 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL27721857 | 0.76 | TRPA1 (0.45) | TRPA1ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL1372350 | 0.76 | ALDH1A1 (0.33) | TRPA1ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL3534917 | 0.76 | ALDH1A1 (0.33) | TRPA1ALDH1A1TSHRTDP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735577-B2 | 1,3,5-triazine derivative, process for producing same, and organic electroluminescent element comprising same as constituent component | TOSOH CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2351750-B1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME AS CONSTITUENT | TOSOH CORP (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20110190494-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | TOSOH CORPORATION (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2351750-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | Tosoh Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7829566-B2 | Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | MEDERSKI WERNER | 2010-11-09 | — | — | US | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070293667-A1 | 4-Amino-quinazolines | MEDERSKI WERNER | 2007-12-20 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2004030671-A2 | USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044204-A1 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044204-A1 | 4-amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | TRPA1 1105/4885ALDH1A1 1661/4885TSHR 662/4885 |
| US-20110190494-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | ASH2L, SETDB1, KAT5 | TRPA1 64/4885ALDH1A1 661/4885TSHR 2800/4885 |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | TRPA1 2534/4885ALDH1A1 1459/4885TSHR 696/4885 |
| US-20070293667-A1 | 4-Amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | TRPA1 859/4885ALDH1A1 1858/4885TSHR 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.